首页> 美国卫生研究院文献>other >Novel method versus the Friedewald method for estimating low-density lipoprotein cholesterol in determination of the eligibility for statin treatment for primary prevention in the United States
【2h】

Novel method versus the Friedewald method for estimating low-density lipoprotein cholesterol in determination of the eligibility for statin treatment for primary prevention in the United States

机译:在美国确定用于初次预防的他汀类药物治疗资格的低密度脂蛋白胆固醇估算的新方法与弗里德瓦尔德方法的比较

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Although the Friedewald method has been used as the clinical standard to estimate low-density lipoprotein cholesterol (LDL-C) levels, a novel method with better accuracy was suggested and is now being adopted in real practice. We investigated the effect of this novel method on determining the eligibility for statin treatment for primary prevention in the United States.In this cross-sectional study, we determined the discordance in the statin-eligible population for primary prevention according to the 2 different LDL-C estimating methods based on the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines. Using data from the National Health and Nutrition Examination Survey 2005–2014, we included 5302 nationally representative US adults aged between 40 and 75 years without history of atherosclerotic cardiovascular disease (ASCVD). Sampling weights were used in all statistical analyses to account for complex sampling design and nonresponse.If the Friedewald method is replaced by the novel method for analysis of the fasting samples, 0.2% (95% confidence interval [CI], 0.0–0.8) and 0.4% (95% CI, 0.3–0.6) of the population would no longer be eligible or would become newly eligible for statin treatment, respectively. Among the individuals with a TG level ≥150 mg/dL and LDL-C level estimated using the Friedewald method <70 mg/dL, 11.6% (95% CI, 4.0–29.3) would become newly eligible for the statin treatment when using the novel method.The use of the novel method for estimating LDL-C instead of the Friedewald method would be associated with a small net increase in statin eligibleeeded US adults for primary prevention based on the 2013 ACC/AHA guidelines. Reassessment of individuals’ statin eligibility using the novel method may be beneficial, particularly when their TG level is 150 mg/dL or higher and LDL-CF level is lower than 70 mg/dL.
机译:尽管Friedewald方法已被用作评估低密度脂蛋白胆固醇(LDL-C)水平的临床标准,但仍提出了一种精度更高的新颖方法,目前已在实际中采用。我们调查了这种新方法对确定美国一级预防用他汀类药物治疗资格的影响。在这项横断面研究中,我们根据2种不同的LDL-L值确定了适合他汀类一级预防的人群中的不一致性。基于2013年美国心脏病学会/美国心脏协会(ACC / AHA)指南的C估计方法。使用《 2005-2014年美国国家健康与营养检查调查》中的数据,我们纳入了5302名具有国家代表性的美国成年人,年龄在40至75岁之间,无动脉粥样硬化性心血管疾病(ASCVD)的病史。在所有统计分析中均使用抽样权重来说明复杂的抽样设计和无响应。如果将Friedewald方法替换为用于分析禁食样品的新方法,则0.2%(95%置信区间[CI],0.0-0.8)和分别有0.4%(95%CI,0.3-0.6)人口不再符合资格或将重新成为接受他汀类药物治疗的资格。用弗里德瓦尔德方法估计的TG≥150 mg / dL和LDL-C水平<70 mg / dL的个体中,使用他汀类药物的他汀类药物治疗新资格为11.6%(95%CI,4.0–29.3)。根据2013年ACC / AHA指南,使用新方法估算LDL-C而不是Friedewald方法将与符合他汀类药物/需要美国成年人一级预防的净增加量有关。用这种新方法重新评估他汀类药物的资格可能是有益的,特别是当他们的TG水平为150μmg/ dL或更高且LDL-CF水平低于70μmg/ dL时。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号